'48 weeks' diaporamas de présentation

DHS/PP

2005 Asilomar HIV/AIDS Medical Update David H. Spach, MD Clinical Director, Northwest AIDS Education and Training Center Professor of Medicine, Division of Infectious Diseases University of Washington, Seattle. DHS/PP. HIV/AIDS: 2005 Antiretroviral Therapy Update.

863 views • 67 slides

Michael P. Manns Markus Cornberg Medizinische Hochschule Hannover

PUBLIC HEALTH CHALLENGES FOR CONTROLLING HCV INFECTION. Hepatitis C: Therapeutic options. Michael P. Manns Markus Cornberg Medizinische Hochschule Hannover Dept. of Gastroenterology, Hepatology and Endocrinology Germany. VHPB Meeting, Ferney Voltaire, France May 13 - 14, 2002.

572 views • 47 slides

Ribavirin ( Copegus , Rebetol , Ribasphere )

Ribavirin ( Copegus , Rebetol , Ribasphere ). Prepared by: David Spach, MD and H. Nina Kim, MD Last Updated: February 14, 2014. Ribavirin ( Copegus , Rebetol , Ribasphere ). Background. Ribavirin: Mechanism of Action. Defective HCV Particle. Th2. Th1. CTL. RBV. IFN- ?.

684 views • 33 slides

Thinking of Now and Tomorrow: Emerging Treatment Paradigms

Thinking of Now and Tomorrow: Emerging Treatment Paradigms. Pedro Cahn. Disclosures. Advisory boards : Merck, ViiV Healthcare Research funds : Abbvie , Merck, Richmond, ViiV Healthcare Speaker at educational activities : Abbvie , Gilead, Merck, ViiV Healthcare.

506 views • 32 slides

Design of the RESIST Study Program

Design of the RESIST Study Program. Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK. Tipranavir Clinical Development Plan - Phase II-III Program. RESIST-1 N=500, 24W TPV/RTV vs. PI/RTV +OBR NA, AUS. 1182.52 Phase IIB 500/100 500/200 750/200. Analysis, choose optimal dose.

388 views • 27 slides

Alendronate improves bone mineral density in HIV-infected children and adolescents IMPAACT P1076

Alendronate improves bone mineral density in HIV-infected children and adolescents IMPAACT P1076. Denise L. Jacobson, Jane C. Lindsey, Hans Spiegel, Rohan Hazra, George Siberry, for the IMPAACT P1076 Study Team. Team members have no conflicts of interest to disclose.

471 views • 26 slides

Disclosures and Acknowledgments

Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women.

222 views • 22 slides

DART

Discordance between virological/immunological and clinical outcomes at 48 weeks, in a randomised comparison of ZDV/3TC/NVP and ZDV/3TC/ABC in patients with low CD4 counts in Africa.

377 views • 19 slides

T. Poynard , MD

269 views • 16 slides

288 views • 15 slides

Boosted PI therapy: theoretical basis

Boosted PI therapy: theoretical basis. Drug concentration. treatment-limiting toxicity. Toxicity threshold. Therapeutic window. Efficacy threshold. viral rebound. 0. 0. 24. Time (hours). MaxCmin1 - HIV RNA <400 c/ml ITT - Exposed. 100. saquinavir/r (n=148 ). 80. % patients.

240 views • 14 slides

WINR Study Flat versus Weight-Based Ribavirin Dosing

215 views • 11 slides

Switch to MVC

Switch to MVC. MARCH Study. MARCH Study: switch to MVC. Design. Randomisation 1 : 2 : 2 Open-label. W48. W96. Adults ? 18 years Stable (> 24 weeks) 2 NRTI + PI/r regimen HIV RNA < 200 c/mL CCR5 virus on proviral DNA tropism testing No previous virological failure

93 views • 9 slides

Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A5201 - OREY

Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A5201 - OREY. ACTG A5201: Switch to ATV/r monotherapy. Design. Open-label Single-arm Pilot trial. W6. W48. HIV+ ? 18 years On first ARV regimen with ? 2 NRTI + ? 1 PI for > 48 weeks HIV-1 RNA < 50 c/mL > 48 weeks

173 views • 3 slides

Switch to LPV/r monotherapy - Pilot LPV/r - M03-613 - American Study - KalMo - OK - OK04

Switch to LPV/r monotherapy - Pilot LPV/r - M03-613 - American Study - KalMo - OK - OK04 - KALESOLO - MOST - HIV-NAT 077. HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy.

83 views • 2 slides